Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.45 |
| ▸ | MEN1 | O00255 | 2/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
| ▸ | TP53 | P04637 | 1/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3735195 | 0.96 | HAO1 (0.46) | L3MBTL1MEN1KMT2ATDP1MAPT | |
| SCHEMBL3364352 | 0.88 | L3MBTL1 (0.54) | L3MBTL1MEN1KMT2ATDP1SMN1; SMN2 | |
| SCHEMBL28808835 | 0.88 | L3MBTL1 (0.54) | L3MBTL1MEN1KMT2ATDP1SMN1; SMN2 | |
| SCHEMBL3745326 | 0.88 | L3MBTL1 (0.54) | L3MBTL1MEN1KMT2ATDP1SMN1; SMN2 | |
| SCHEMBL28689462 | 0.88 | L3MBTL1 (0.54) | L3MBTL1MEN1KMT2ATDP1SMN1; SMN2 | |
| SCHEMBL3736446 | 0.83 | ACE (0.49) | L3MBTL1 | |
| SCHEMBL3739685 | 0.83 | MEN1 (0.48) | L3MBTL1MEN1KMT2ATP53CYP1A2 | |
| SCHEMBL30110380 | 0.83 | L3MBTL1 (0.51) | L3MBTL1MEN1KMT2ATDP1MAPT | |
| SCHEMBL13041390 | 0.82 | HPGD (0.49) | MEN1KMT2ASMN1; SMN2HPGDCYP1A2 | |
| SCHEMBL29191664 | 0.82 | KMT2A (0.51) | L3MBTL1MEN1KMT2ATDP1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100280034-A1 | Modulation of pathogenicity | QUONOVA, LLC | 2010-11-04 | — | — | US | disclosed |
| US-7338969-B2 | Modulation of pathogenicity | QUONOVA, LLC (US) | 2008-03-04 | — | — | US | disclosed |
| US-20070208012-A1 | Modulation of Pathogenicity | QUONOVA, LLC | 2007-09-06 | — | — | US | disclosed |
| US-20070203128-A1 | Modulation of Pathogenicity | QUONOVA, LLC | 2007-08-30 | — | — | US | disclosed |
| US-20070197492-A1 | Modulation of Pathogenicity | QUONOVA, LLC | 2007-08-23 | — | — | US | disclosed |
| US-20070196340-A1 | Modulation of Pathogenicity | QUONOVA, LLC | 2007-08-23 | — | — | US | disclosed |
| US-20070184014-A1 | Modulation of Pathogenicity | QUONOVA, LLC | 2007-08-09 | — | — | US | disclosed |
| US-20070093534-A1 | Modulation of Pathogenicity | QUONOVA, LLC | 2007-04-26 | — | — | US | disclosed |
| EP-1622890-A2 | BLOCKERS OF THE QUORUM SENSING SYSTEM OF GRAM-NEGATIVE BACTERIA | 4SC AG (DE) | 2006-02-08 | — | — | EP | disclosed |
| US-20040235914-A1 | Modulation of pathogenicity | 4 SC AG (DE) | 2004-11-25 | — | — | US | disclosed |
| WO-2004099175-A2 | BLOCKERS OF THE QUORUM SENSING SYSTEM OF GRAM-NEGATIVE BACTERIA | 4SC AG (DE) | 2004-11-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070197492-A1 | Modulation of Pathogenicity | ANTXR2, Q6ZSR9, PGLS | L3MBTL1 312/4885MEN1 2782/4885KMT2A 4236/4885 |
| US-20070203128-A1 | Modulation of Pathogenicity | ANTXR2, Q6ZSR9, PGLS | L3MBTL1 312/4885MEN1 2782/4885KMT2A 4236/4885 |
| US-20070093534-A1 | Modulation of Pathogenicity | NR1H4, NR1I3, NR1H2 | L3MBTL1 1764/4885MEN1 2504/4885KMT2A 2108/4885 |
| US-20040235914-A1 | Modulation of pathogenicity | Q6ZSR9, CCL11, CFH | L3MBTL1 429/4885MEN1 2757/4885KMT2A 2689/4885 |
| US-20070208012-A1 | Modulation of Pathogenicity | ANTXR2, Q6ZSR9, PGLS | L3MBTL1 312/4885MEN1 2782/4885KMT2A 4236/4885 |
| US-20100280034-A1 | Modulation of pathogenicity | NR1H4, NR1I3, NR1H2 | L3MBTL1 1764/4885MEN1 2504/4885KMT2A 2108/4885 |
| US-20070184014-A1 | Modulation of Pathogenicity | ANTXR2, Q6ZSR9, PGLS | L3MBTL1 312/4885MEN1 2782/4885KMT2A 4236/4885 |
| US-20070196340-A1 | Modulation of Pathogenicity | NR1H4, NR1I3, NR1H2 | L3MBTL1 1764/4885MEN1 2504/4885KMT2A 2108/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.